Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

BIOSTEM TECHNOLOGIES logo

BIOSTEM TECHNOLOGIES

US$5.13

US$45.9m

25.17%

-51.99%

Dashboard Funda..tals Deep..lue Prediction Screener Map

BIOSTEM TECHNOLOGIES Overview

Industry: Biotechnology

Sector: Healthcare

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

BIOSTEM TECHNOLOGIES is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review BIOSTEM TECHNOLOGIES in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



BIOSTEM TECHNOLOGIES Competitors

BIOSTEM TECHNOLOGIES operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

BIOSTEM TECHNOLOGIES

US$5.13

US$45.9m

25.17%

-51.99%